Date: 31st August, 2026
Regulatory Compliance Disclosure
The company has made a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding receipt of a significant certification.
Certification Details
- Certification Received: WHO-GMP (Good Manufacturing Practices) Certification
- Facility: First pharmaceutical formulation manufacturing facility located at Jadcherla, Hyderabad, Telangana
- Issuing Authority: Licensing Authority, Government of Telangana
- Inspection Date: 14th July, 2026
- Certificate Date: 27th August, 2026
- Validity Period: Up to 26th August, 2029 (three years)
Operational Impact
- The certification confirms compliance of the site with Good Manufacturing Practices for the certified dosage form, categories and activities
- The company has commenced manufacturing of its initially approved products at the facility
- The company awaits approval for some additional products
- Going forward, the company will progressively add more products to strengthen and expand its product portfolio for its target international markets
- All expansions are subject to applicable regulatory requirements and approvals
Financial and Operational Assessment
- The receipt of WHO-GMP Certification is described as a significant milestone in the Company's journey towards establishing its own manufacturing capabilities
- The certification strengthens the company's quality and manufacturing credentials
- The company does not anticipate any adverse impact on its existing business operations
- The impact is not quantifiable in monetary terms at this stage
Additional Information
- The disclosure was signed by Aman Purohit, Company Secretary & Compliance Officer (ICSI Membership No.: A59345)